Abstract

In their January 2010 Drug Safety Update, the UK MHRA warns that treatment with either bevacizumab [Avastin] or sunitinib [Sutent

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call